Novo Nordisk got a peptide pill through the stomach by pairing it with SNAC

GLP-1 drugs worked, but the class had historically meant injections. Novo Nordisk's problem was that peptides are usually too fragile and too poorly permeable to survive oral dosing: enzymes, pH, and membrane barriers all work against them.

Novo's answer was not a capsule that carried semaglutide safely all the way through the gut. It co-formulated semaglutide with SNAC, a carrier molecule from Emisphere. As the tablet erodes in the stomach, SNAC locally buffers pH, reduces degradation, promotes semaglutide monomerization, and makes nearby gastric cells temporarily more permeable.

That made oral semaglutide the first oral GLP-1 receptor agonist approved for type 2 diabetes in 2019. The pill still came with strict dosing rules, but the mechanism turned a biologic that looked injectable by nature into a daily tablet.

Protect the peptide only where it must cross

SNAC acts locally and transiently, so the formulation changes the absorption site rather than asking the whole digestive tract to cooperate.

The carrier was matched to semaglutide's properties; the same enhancer did not simply make every GLP-1 peptide orally viable.

Stomach absorption avoided waiting for intestinal delivery, where peptides face long exposure to digestive barriers.

Once absorbed, semaglutide's long half-life made once-daily oral dosing workable despite low bioavailability.

A delivery problem may not need a new route through the body; it may need a small, local window where the old route briefly behaves differently.

Oral semaglutide was approved in September 2019 for adults with type 2 diabetes. Reviews of the PIONEER program reported glycemic and weight effects comparable enough to make the oral route clinically useful, while noting the empty-stomach dosing routine as a practical constraint.